)
Dr. Sharyl Fyffe-Maricich
Vice President of Molecular and Cell Sciences,
Ultragenyx
Dr. Sharyl Fyffe-Maricich, received a BS degree from Queen’s University in Canada, and a PhD in Human and Molecular Genetics from Baylor College of Medicine. Following her postdoctoral training at Case Western where she worked to develop therapies for Multiple Sclerosis, Sharyl joined the University of Pittsburgh School of Medicine faculty as a tenure track Assistant Professor of Pediatric Neurology.
Sharyl currently leads teams of scientists at Ultragenyx focused on the preclinical development of ASO and AAV9 gene therapy programs for several neurogenetic disorders. Sharyl is also currently serving as a scientific advisory board member for the PCH19 Epilepsy Alliance and the International FoxP1 Foundation.